Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLURP: qFME with Bevacizumab-800CW and Cetuximab-800CW in Barrett's Esophagus
NCT05745857Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2023
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, cetuximab in Barrett's esophagus, esophageal adenocarcinoma (EAC), sponsored by University Medical Center Groningen. Started Sep 2023; status: recruiting.
02
Drugs
bevacizumabcetuximab
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05745857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745857.